cost-CM1102
Working Groups
WG1 (A Casnati)
- Glycoconjugates for drug/gene delivery
- Aim: to exploit the use of multivalent protein-carbohydrate interactions to deliver macromolecular drugs (e.g., siRNA, antibodies) into specific cell types
WG2 (R Pieters)
- Glycoconjugates for Diagnostics
- Aim: to develop methods for adhesion-based detection of carbohydrate-binding proteins involved in diseases (e.g., antibodies) that are key biomarkers for the diagnosis and prognosis of cancer, heart disease and autoimmune diseases
WG3 (V Kren)
- Glycoconjugates for use as vaccines / modulators of the immune system
- Aim: to develop nanoscale glycoconjugates that can activate the innate and adaptive immune responses to protect against infectious diseases or treat existing conditions e.g., cancer
WG4 (A Imberty)
- Glycoconjugates as anti-pathogenic agents
- Aim: to develop nanoscale glycoconjugates that can be used to prevent infection by viruses, bacteria and fungi, and to reverse the formation of biofilms that form during persistent infections